CGC vs. ARDX, ZYME, LENZ, OCS, PRAX, ORIC, COGT, CMRX, CDMO, and AVXL
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Oculis (OCS), Praxis Precision Medicines (PRAX), Oric Pharmaceuticals (ORIC), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.
Canopy Growth vs. Its Competitors
Ardelyx (NASDAQ:ARDX) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.
Ardelyx has higher revenue and earnings than Canopy Growth. Ardelyx is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Ardelyx has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
In the previous week, Ardelyx had 4 more articles in the media than Canopy Growth. MarketBeat recorded 8 mentions for Ardelyx and 4 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.91 beat Ardelyx's score of 0.63 indicating that Canopy Growth is being referred to more favorably in the news media.
Ardelyx currently has a consensus price target of $10.89, suggesting a potential upside of 179.20%. Canopy Growth has a consensus price target of $2.00, suggesting a potential upside of 76.99%. Given Ardelyx's stronger consensus rating and higher probable upside, research analysts plainly believe Ardelyx is more favorable than Canopy Growth.
58.9% of Ardelyx shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 1.3% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Ardelyx has a net margin of -14.86% compared to Canopy Growth's net margin of -195.76%. Ardelyx's return on equity of -34.45% beat Canopy Growth's return on equity.
Summary
Ardelyx beats Canopy Growth on 14 of the 17 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
This page (NASDAQ:CGC) was last updated on 7/1/2025 by MarketBeat.com Staff
